Wednesday, 23 Jul 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • VIDEO
  • ScienceAlert
  • White
  • Watch
  • Trumps
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Novo Nordisk’s Ozempic and Wegovy, long in shortage, now available
Health and Wellness

Novo Nordisk’s Ozempic and Wegovy, long in shortage, now available

Last updated: November 3, 2024 8:05 pm
Share
Novo Nordisk’s Ozempic and Wegovy, long in shortage, now available
SHARE

Novo Nordisk’s popular diabetes and obesity medications, Ozempic and Wegovy, have been listed on the Food and Drug Administration’s drug shortage list for over two years. However, as of Wednesday, all doses of semaglutide, the active ingredient in these medications, are now listed as available on the FDA’s website. This development raises the possibility that the medications could soon be removed from the shortage list entirely, which could have implications for compounding pharmacies and patients who rely on compounded drugs.

Semaglutide is the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy. Different doses of semaglutide have been intermittently listed in shortage over the past two years. With all doses now marked as available, the FDA is in discussions with Novo to determine if the company can adequately meet the demand for these medications moving forward. It’s important to note that the “available” designation does not necessarily mean that the drug is no longer in shortage.

FDA spokesperson Amanda Hills stated that the agency is currently assessing whether the demand for semaglutide exceeds the available supply. The decision to remove the medication from the shortage list will depend on the outcome of these discussions between the FDA and Novo.

It’s crucial for patients and healthcare providers to stay informed about the availability of these important medications. The potential resolution of the shortage could bring relief to those who rely on Ozempic and Wegovy for managing their diabetes and obesity. As the situation evolves, it will be important to monitor updates from both Novo Nordisk and the FDA regarding the status of semaglutide and its availability in the market.

See also  We've Come So Far, So Why Aren't Women Thriving?
TAGGED:LongNordisksNovoOzempicShortageWegovy
Share This Article
Twitter Email Copy Link Print
Previous Article Affirm launches in the UK, as ‘buy now, pay later’ market faces regulatory overhaul Affirm launches in the UK, as ‘buy now, pay later’ market faces regulatory overhaul
Next Article FACT CHECK: In Presidential Debate, Harris Deflects on Border Record FACT CHECK: In Presidential Debate, Harris Deflects on Border Record
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Emilie Kiser Files Lawsuit Over Son Trigg’s Death Records

The investigation into the tragic death of Emilie Kiser's 3-year-old son, Trigg Chapman Kiser, has…

June 2, 2025

Billionaire Ken Griffin’s hedge funds at Citadel are all in the green for 2025

Billionaire investor Ken Griffin's hedge funds at Citadel have continued to perform well in 2025,…

July 1, 2025

Man Accused In The Burning Death Of A Woman On A New York Subway Appears In Court

In a tragic incident in New York City, a man allegedly set a woman on…

December 24, 2024

Higher cigarette taxes may improve childhood survival

A recent study led by researchers at Karolinska Institutet suggests that implementing higher taxes on…

April 29, 2025

Dollar dithers, yen gains on BOJ rate hike bets

The global currency market is experiencing turbulence as trade tensions escalate, impacting the value of…

March 13, 2025

You Might Also Like

Rethink the 10,000-a-day step goal; study suggests fewer steps are just as effective
Health and Wellness

Rethink the 10,000-a-day step goal; study suggests fewer steps are just as effective

July 23, 2025
Kennedy adopts controversial ACIP recommendation on thimerosal
Health and Wellness

Kennedy adopts controversial ACIP recommendation on thimerosal

July 23, 2025
Study finds stopping HRT leads to a period of higher risk of bone fracture for most women
Health and Wellness

Study finds stopping HRT leads to a period of higher risk of bone fracture for most women

July 23, 2025
In India, Air Pollution Can Increase The Risk Of Preterm Birth: Study
Health and Wellness

In India, Air Pollution Can Increase The Risk Of Preterm Birth: Study

July 23, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?